T
TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.
Investor insights
Funding rounds participated in
$250K sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2014
Funding rounds raised
Total raised
$250K
from 1 investors over 1 rounds
T
TC BioPharm raised $250K on December 12, 2024
Investors: ScaleReady